Question-and-Answer Session
Operator
Thank you. (Operator Instructions). And we'll go to the line of Roopesh Patel of UBS. Please go ahead.
Roopesh Patel - UBS
Thank you. I've got a couple of questions. First on Pristiq in VMS, can you confirm that you are expecting a full approval on July 23, based on your discussions to date with the FDA and can you also summarize for us the cardiovascular risk profile of the drug based on all the clinical studies that Wyeth has completed so far? And how does it compare to the other SNRIs and how do you expect it will be reflected on the label? And then separately on the pipeline if you could just elaborate on which other product besides bapineuzumab that we expect to start Phase III trials later this year? Thanks.
Greg Norden
Okay. Bernand you want to take that?
Bernard Poussot
Yes, on Pristiq first. I can confirm that we are few days away from getting action letter from the FDA, so we'd like to wait for that response from FDA for further comments. On the cardiovascular profile we standby the safety of the product. We've analyzed the database on the cardiovascular field and believe that you know what we see and the product is no different than what you would observe in the general population of that age and condition. So overall, we believe we have a very safe product and stand by that. Its very early for me to speculate on how the labeling would look, so I would not do that and then you had a question on bapineuzumab but I think Justin wants to address that.
Justin Victoria
Roopesh this is Justin obviously there has been a lot of comment about bapineuzumab or AAB with our plans to initiate our Phase III trials later this year we are preparing to dialogue with the regulators to ensure we get adequate buy in on the program working with our partner Solvay so we're continue to be very excited about that opportunity.
We have several of compounds that are progressing nicely in Phase II that were targeted for Phase III initiation later this year. We haven't identified exactly what they are I can tell you a number of compounds in our oncology pipeline are moving along that include HKI and SKI in oncology., We are looking at one of the other Wyeth compounds and Alzheimer is potentially moving from Phase II to Phase III but I think we'll hold off on identifying the specific compounds until such time which we do make those transitions.
- To read the full transcript on Seeking Alpha, click here »
